COMP <GO>
TARS vs MRK // GROSS PROFIT MARGIN
Tarsus Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: TARS 3
— MRK 7
■ METRIC PARITY
LAST: $74.85 (+0.88%) • MKT CAP: $3.66B
gross-margins
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TARS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.10% | 20.70% | -44.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.61% | 3.42% | -4.03 | MRK | /fcf-yield <GO> |
| Operating Margin | -15.70% | 34.30% | -50.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | -14.60% | 28.10% | -42.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 146.70% | 1.30% | +145.40 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.19 | 5.19 | +5.00 | TARS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.4 | 51.7 | +1.70 | TARS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.66B | $361.02B | -$357.36B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TARS REV | MRK REV | TARS GROSS % | MRK GROSS % | TARS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $451.4M | $65.01B | — | 74.8% | -$22.3M | $12.36B |
| FY 2024 | $183.0M | $64.17B | — | 76.3% | -$84.6M | $18.10B |
| FY 2023 | $17.4M | $60.12B | — | — | -$117.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARS // BETA —
MRK // BETA 0.92